Product Profiles: Colorectal Cancer - New Drug Combinations and Label Expansions will Increase Competition

Sep 19, 2011, 11:28 ET from Reportlinker

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Product Profiles: Colorectal Cancer – New drug combinations and label expansions will increase competition

http://www.reportlinker.com/p0618129/Product-Profiles-Colorectal-Cancer-–-New-drug-combinations-and-label-expansions-will-increase-competition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The colorectal cancer pipeline has grown as pharmaceutical developers are attracted by the unmet need present in this high-incidence cancer type. Cytotoxics remain an integral part of colorectal cancer treatment, but there are a growing number of targeted therapies on the market and in the pipeline. Competition will increase following label expansions and development of new drug combinations. Analysis of marketed colorectal cancer drugs – development history, key clinical trial data, and assessment of clinical and commercial attractiveness. Analysis of marketed drugs in comparison to current standard of care. In-depth analysis of late-stage pipeline drugs – development overview, SWOT analysis, and assessment of clinical and commercial attractiveness. Discussion and assessment of pipeline drugs' ability to meet unmet needs in treatment of colorectal cancer. Eloxatin and Camptosar continue to compete in the metastatic setting through their use in the FOLFOX and FOLFIRI regimens. However, introduction of generic forms has begun to erode branded sales. Xeloda oral formulation has boosted sales in the EU, but has had a negative impact on uptake in the US. Targeted therapies maintain competition for greater market share. Avastin remains dominant, particularly in the US, but Erbitux's label expansion in the EU in 2008 will increase pressure on Avastin in the first-line. Vectibix may finally be able to compete for a larger share of the EU market pending the EMA's final decision. VEGF targeted drugs dominate the late-stage pipeline. Zaltrap is the most advanced drug in the late-stage pipeline and looks set to enter the market in combination with FOLFIRI as a second-line treatment. The development of drugs in combination with existing therapies could increase efficacy and further boost uptake. Understand the dynamics of colorectal cancer therapy and identify the market leaders in this competitive indication. Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy. Understand how pipeline drugs will be used with current therapies and how the market is access ed through less competitive treatment settings

OVERVIEW

Catalyst

Summary

EXECUTIVE SUMMARY

Strategic scoping and focus

Datamonitor key findings

Related reports

PRODUCT OVERVIEW

Key marketed and pipeline products

Datamonitor's assessment summary

MARKETED PRODUCT PROFILES

Camptosar (irinotecan; Pfizer)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Eloxatin (oxaliplatin; Sanofi)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Xeloda (capecitabine; Roche/Genentech/Chugai)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Avastin (bevacizumab; Genentech/Roche/Chugai)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Vectibix (panitumumab; Amgen)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Other marketed drugs for colorectal cancer

TS-1 (tegafur, gimeracil, oxonic acid; Taiho)

UFT (tegafur, uracil; Taiho/Merck)

PIPELINE PRODUCT PROFILES

Brivanib (BMS-582664; Bristol-Myers Squibb)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Imprime PGG (Biothera)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

OncoVAX (Intracel/Vaccinogen)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Perifosine (KX-040; AEterna Zentaris/Keryx Biopharmaceuticals)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Ramucirumab (Eli Lilly)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Regorafenib (Bayer)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Zaltrap (aflibercept/VEGF-Trap; Regeneron/Sanofi)

Drug overview

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

Market definition

PharmaVitae Explorer database

Contributing experts

Report methodology

TABLES

Table: Key marketed and pipeline products for colorectal cancer, 2011

Table: Camptosar – drug profile, 2011

Table: Overview of major colorectal cancer approvals for Camptosar

Table: Overview of pivotal trial data for Camptosar in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Camptosar for colorectal cancer, 2011

Table: Eloxatin – drug profile, 2011

Table: Overview of major colorectal cancer approvals for Eloxatin

Table: Overview of pivotal trial data for Eloxatin in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Eloxatin for colorectal cancer, 2011

Table: Xeloda – drug profile, 2011

Table: Overview of major colorectal cancer approvals for Xeloda

Table: Overview of pivotal trial data for Xeloda in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Xeloda for colorectal cancer, 2011

Table: Avastin – drug profile, 2011

Table: Overview of major CRC approvals for Avastin

Table: Overview of pivotal trial data for Avastin in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Avastin for colorectal cancer, 2011

Table: Erbitux – drug profile, 2011

Table: Overview of major colorectal cancer approvals for Erbitux

Table: Overview of pivotal trial data for Eloxatin in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Erbitux for colorectal cancer, 2011

Table: Vectibix – drug profile, 2011

Table: Overview of major CRC approvals for Vectibix

Table: Overview of pivotal trial data for Vectibix in colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Vectibix for colorectal cancer, 2011

Table: TS-1 – drug profile, 2011

Table: UFT – drug profile, 2011

Table: Brivanib – drug profile, 2011

Table: Clinical development of brivanib, 2011

Table: Ability of brivanib to meet unmet needs in second-line colorectal cancer, 2011

Table: Datamonitor drug assessment summary of brivanib for colorectal cancer, 2011

Table: Imprime PGG – drug profile, 2011

Table: Clinical development of Imprime PGG, 2011

Table: Ability of Imprime PGG to meet unmet needs in second-line colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Imprime PGG for colorectal cancer, 2011

Table: OncoVAX – drug profile, 2011

Table: Clinical development of OncoVAX, 2011

Table: Ability of OncoVAX to meet unmet needs in adjuvant colorectal cancer, 2010

Table: Datamonitor drug assessment summary of OncoVAX for colorectal cancer, 2011

Table: Perifosine – drug profile, 2011

Table: Clinical development of perifosine, 2011

Table: Ability of perifosine to meet unmet needs in second-line colorectal cancer, 2011

Table: Datamonitor drug assessment summary of perifosine for colorectal cancer, 2011

Table: Ramucirumab – drug profile, 2011

Table: Clinical development of ramucirumab, 2011

Table: Summary of Phase I clinical trial data for ramucirumab in solid tumors

Table: Datamonitor drug assessment summary of ramucirumab for colorectal cancer, 2011

Table: Regorafenib – drug profile, 2011

Table: Clinical development of regorafenib, 2011

Table: Summary of Phase I clinical trial data for regorafenib in advanced refractory colorectal cancer

Table: Datamonitor drug assessment summary of regorafenib for colorectal cancer, 2011

Table: Zaltrap – drug profile, 2011

Table: Clinical development of Zaltrap, 2011

Table: Ability of Zaltrap to meet unmet needs in second-line colorectal cancer, 2011

Table: Datamonitor drug assessment summary of Zaltrap for colorectal cancer, 2011

Table: Summary of therapeutic classes in colorectal cancer by ATC code, 2011

FIGURES

Figure: Datamonitor's drug assessment summary of key marketed drugs for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of pipeline drugs for metastatic colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of pipeline drugs for early-stage colorectal cancer, 2011

Figure: Camptosar's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Camptosar for colorectal cancer, 2011

Figure: Eloxatin's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Eloxatin for colorectal cancer, 2011

Figure: Xeloda's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Xeloda for colorectal cancer, 2011

Figure: Avastin's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Avastin for colorectal cancer, 2011

Figure: Erbitux's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Erbitux for colorectal cancer, 2011

Figure: Vectibix's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Vectibix for colorectal cancer, 2011

Figure: Phase I/II results for second-line brivanib and Erbitux in metastatic colorectal cancer

Figure: Brivanib's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of brivanib for metastatic colorectal cancer, 2011

Figure: Phase Ib/IIa results for Imprime in combination with Erbitux with or without irinotecan in metastatic colorectal cancer

Figure: Imprime PGG's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Imprime PGG for metastatic colorectal cancer, 2011

Figure: Phase IIIa results for adjuvant OncoVAX in Stage II and III colorectal cancer

Figure: OncoVAX's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of OncoVAX for colorectal cancer, 2011

Figure: Phase II results for second-/third-line perifosine and Xeloda in metastatic colorectal cancer

Figure: Perifosine's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of perifosine for metastatic colorectal cancer, 2011

Figure: Ramucirumab's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of ramucirumab for metastatic colorectal cancer, 2011

Figure: Regorafenib's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of regorafenib for metastatic colorectal cancer, 2011

Figure: Phase II results for second-line Zaltrap monotherapy in metastatic colorectal cancer

Figure: Zaltrap's SWOT analysis for colorectal cancer, 2011

Figure: Datamonitor's drug assessment summary of Zaltrap for metastatic colorectal cancer, 2011

Figure: The PharmaVitae Explorer

Companies Mentioned

Anheuser-Busch InBev SA/NV, Brossard SA, Chattem, Inc., Hutchison 3G UK Limited, Merck KGaA, Omnicom Group Inc., Puig, Schindler Holding Ltd.

To order this report:

Pathology Industry: Product Profiles: Colorectal Cancer – New drug combinations and label expansions will increase competition

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Contact: Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com